



For information contact:

Corporate Contact

Katrine Bosley
Vice President Business Development
Adnexus Therapeutics, Inc.
781-891-3745
pr@adnexustx.com

Media Contact

Paul Kidwell
Suda Communications
617-296-3854
paulkidwell@comcast.net

Adnexus Therapeutics Announces Additional Phase I and Preclinical Data on CT-322 at 6th International Congress on Targeted Therapies in Cancer

Waltham, MA – August 27, 2007 – Adnexus Therapeutics, Inc. today announced that the company presented additional Phase I and preclinical data on Angiocept (CT-322), the company's novel anti-angiogenesis agent, at The 6th International Congress on Targeted Therapies in Cancer that was held in Washington, DC at the Renaissance Mayflower Hotel August 24-26, 2007. The presentation titles and the associated speakers were as follows:

Title: "Adnectins - A novel class of protein therapeutics"

Speaker: Eric Furfine, Ph.D., SVP of Research and Preclinical Development at Adnexus
Saturday, August 25th at 1:30pm.

Title: "Phase I data with Adnectins"

Speaker: Christopher, Sweeney, M.D., Indiana University
Saturday, August 25th at 1:50pm.

Angiocept (CT-322), Adnexus' first drug candidate, is in an ongoing Phase 1 trial in oncology in the United States. Angiocept is an Adnectin that was designed to be both a potent and highly specific antagonist of the vascular endothelial growth factor receptor 2 (VEGFR-2). VEGFR-2 activation is believed to be the primary driver of the growth of new blood vessels that support tumor growth. Angiocept has been demonstrated in preclinical studies to block activation of VEGFR-2 by all of its known protein activators, VEGF-A, VEGF-C, and VEGF-D.

Adnectins are a novel, proprietary class of targeted biologics that are derived from a well-characterized protein, fibronectin, that is prevalent throughout the human body. Adnexus is the exclusive developer of Adnectins.

About Adnexus Therapeutics

Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of a new class of drugs, Adnectins. Adnexus' first product candidate, Angiocept (CT-322), is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that enables rapid optimization of protein therapeutics. The company is funded by five leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, Venrock, and HBM BioVentures.



Adnectin™, Adnexus™ Therapeutics and PROfusion™ are trademarks of Adnexus™ Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus™ Therapeutics.

###